BRAF and melanoma: Examples of this are the discovery of MEK reactivation in RAF inhibitor‐treated B‐RAF‐mutant melanoma cells and the emergence of drug‐resistant mutations in EGFR in lung cancer, both of which have led to new treatment strategies with improved success (Robert et al, 2015; Mok et al, 2017).